Sudden cardiac death prevention study
This article was originally published in The Gray Sheet
Executive Summary
Cambridge Heart will launch a 50-center MASTER trial in early 2003 of its microvolt T-wave Alternans non-invasive test for assessing risk of SCD. The trial will examine 600 patients with previous MI and ejection fraction of 30% or less; an additional 1,200 will be enrolled in a registry of patients with ejection fraction between 30%-40%. The trial's inclusion criteria were set following the release of recent AHA/ACC guidelines (1"The Gray Sheet" Sept. 30, 2002, p. 9). Results are expected by 2005...
You may also be interested in...
T-Wave Alternans Will Help ICDs Meet Market Potential – Cambridge Heart
Further adoption of Cambridge Heart's Microvolt T-Wave Alternans (MTWA) non-invasive test for assessing risk of sudden cardiac death will boost the number of ICD-eligible patients referred to electrophysiologists, the company maintains
ICD Guidelines From ACC/AHA/NASPE Embrace MADIT-II Prophylactic Use
ICDs should be implanted in heart attack victims whose left-ventricular ejection fraction is 30% or less one month after the event and three months post-revascularization, according to new practice guidelines issued jointly by ACC, AHA and NASPE
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.